Aromatase inhibitors constitute the preferred therapeutic agent for the treatment of postmenopausal ER+ breast cancer patients, in the adjuvant setting to prevent recurrence of early-stage breast cancer, and as first-line and later agents to treat metastatic breast cancer [53]. The gene discussed is CYP19A1; the disease is breast carcinoma.